JP2023503399A5 - - Google Patents
Info
- Publication number
- JP2023503399A5 JP2023503399A5 JP2022527137A JP2022527137A JP2023503399A5 JP 2023503399 A5 JP2023503399 A5 JP 2023503399A5 JP 2022527137 A JP2022527137 A JP 2022527137A JP 2022527137 A JP2022527137 A JP 2022527137A JP 2023503399 A5 JP2023503399 A5 JP 2023503399A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- pharmaceutical combination
- combination product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/120040 | 2019-11-21 | ||
| CN2019120040 | 2019-11-21 | ||
| PCT/CN2020/130003 WO2021098758A1 (en) | 2019-11-21 | 2020-11-19 | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023503399A JP2023503399A (ja) | 2023-01-30 |
| JP2023503399A5 true JP2023503399A5 (https=) | 2023-11-29 |
Family
ID=75980301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527137A Pending JP2023503399A (ja) | 2019-11-21 | 2020-11-19 | 抗ｔｉｍ３抗体と組み合わせて抗ｏｘ４０抗体を用いるがんを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230002501A1 (https=) |
| EP (1) | EP4061845A4 (https=) |
| JP (1) | JP2023503399A (https=) |
| KR (1) | KR20220103105A (https=) |
| CN (2) | CN118320076A (https=) |
| AU (1) | AU2020387990A1 (https=) |
| BR (1) | BR112022008184A2 (https=) |
| CA (1) | CA3157319A1 (https=) |
| IL (1) | IL293117A (https=) |
| MX (1) | MX2022006149A (https=) |
| WO (1) | WO2021098758A1 (https=) |
| ZA (1) | ZA202204252B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023746A2 (pt) | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| SG10201708048XA (en) * | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| HUE045065T2 (hu) * | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| DK3303396T5 (da) * | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| AU2016364891A1 (en) * | 2015-12-03 | 2018-06-07 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| US11203637B2 (en) * | 2016-08-26 | 2021-12-21 | Beigene, Ltd. | Anti-Tim-3 antibodies and use thereof |
| JP2021501801A (ja) * | 2017-11-01 | 2021-01-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の処置に用いるための免疫刺激アゴニスト抗体 |
| CN111393529B (zh) * | 2018-01-29 | 2022-02-22 | 康源博创生物科技(北京)有限公司 | 与ox40l非竞争结合的抗ox40抗体 |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
-
2020
- 2020-11-19 JP JP2022527137A patent/JP2023503399A/ja active Pending
- 2020-11-19 BR BR112022008184A patent/BR112022008184A2/pt unknown
- 2020-11-19 KR KR1020227015822A patent/KR20220103105A/ko active Pending
- 2020-11-19 CA CA3157319A patent/CA3157319A1/en active Pending
- 2020-11-19 CN CN202410292008.3A patent/CN118320076A/zh active Pending
- 2020-11-19 MX MX2022006149A patent/MX2022006149A/es unknown
- 2020-11-19 CN CN202080075615.4A patent/CN114641500B/zh active Active
- 2020-11-19 IL IL293117A patent/IL293117A/en unknown
- 2020-11-19 WO PCT/CN2020/130003 patent/WO2021098758A1/en not_active Ceased
- 2020-11-19 US US17/778,689 patent/US20230002501A1/en not_active Abandoned
- 2020-11-19 AU AU2020387990A patent/AU2020387990A1/en active Pending
- 2020-11-19 EP EP20889435.2A patent/EP4061845A4/en active Pending
-
2022
- 2022-04-14 ZA ZA2022/04252A patent/ZA202204252B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024037894A5 (https=) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2024020298A5 (https=) | ||
| JP2020103301A5 (https=) | ||
| JP2021531005A5 (https=) | ||
| JP2023503396A5 (https=) | ||
| JP2021531764A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| HRP20250199T1 (hr) | Bispecifična anti-bcma x anti-cd3 antitijela i njihove upotrebe | |
| JP2021527431A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| IL318482A (en) | Pd-1 inhibitor for use in a method of treating skin cancer | |
| IL276695A (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| CN109843927A (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| JP2017535257A5 (https=) | ||
| JP2020515247A5 (https=) | ||
| JP2023543152A5 (https=) | ||
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2022533538A5 (https=) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2023502323A5 (https=) | ||
| JP2021512652A5 (https=) | ||
| JP2020513759A5 (https=) | ||
| JP2024504331A5 (https=) |